BPC-157 dosage is the single most common question people ask when they first discover this peptide, and for good reason. Get it wrong, and weeks of protocol go to waste. Get it right, and the results can be remarkable.
Body Protection Compound-157 (BPC-157) is a synthetic peptide derived from a protein found in human gastric juice. It has gained massive popularity for its ability to accelerate tendon repair, support gut lining restoration, and reduce inflammation across soft tissues. Even though being the most-prescribed research peptide globally, it remains backed primarily by preclinical animal data rather than completed Phase 2 or Phase 3 human trials.
That distinction matters. It means dosing guidance comes from practitioner experience, animal study extrapolation, and emerging clinical observation, not from FDA-approved labeling.
This guide breaks down the standard BPC-157 dosage ranges, explains how administration method changes what the peptide can do, and lays out practical protocols for both tendon injuries and gastrointestinal healing. Whether someone is recovering from a stubborn Achilles tendon issue or managing chronic gut inflammation, the right dose, route, and cycle length make all the difference among peptides for recovery.
How BPC-157 Works for Tendon Repair and Gut Restoration
BPC-157 operates through two primary biological pathways: VEGF (vascular endothelial growth factor) upregulation and nitric oxide (NO) signaling. Together, these mechanisms drive new blood vessel formation, reduce local inflammation, and accelerate collagen deposition at injury sites.
For tendon repair specifically, BPC-157 activates fibroblasts, the cells responsible for producing the structural matrix that tendons are built from. Animal studies have shown accelerated healing of severed Achilles tendons, rotator cuff tears, and medial collateral ligament injuries when BPC-157 was administered near the injury site. The peptide also appears to upregulate growth factor receptors in connective tissue, which helps explain why practitioners report faster recovery timelines in patients with localized tendon and ligament damage.
The gut healing mechanism is different but equally compelling. BPC-157 has demonstrated protective effects on gastric mucosa in animal models, counteracting damage caused by NSAIDs, alcohol, and stress-induced ulceration. It supports restoration of the intestinal barrier, the tight junction integrity that breaks down in conditions like leaky gut, IBD, and chronic gastritis.
One important genetic variable: individuals with specific VEGFA (rs2010963) high-expression variants may respond more strongly to BPC-157. Conversely, carriers of the NOS3 G894T variant may experience slower healing responses due to impaired nitric oxide production. Genetic testing through services like those referenced at ThePeptideList can help identify these differences before starting a protocol.
The key takeaway is that BPC-157 works locally, not systemically. This is why injection site selection matters enormously for tendon injuries, and why oral administration makes more sense for gut-related goals. For systemic repair needs, our BPC-157 vs TB-500 comparison helps clarify which peptide fits.
Standard BPC-157 Dosage Ranges by Administration Method
The standard BPC-157 dosage falls between 250 and 500 mcg per injection, administered twice daily approximately 12 hours apart. But the route of administration changes both the effective dose and what the peptide actually targets.
Here are the three primary methods:
- Subcutaneous injection (most common): 250–500 mcg per dose, 2x daily. Inject near the injury site for localized effect. This is the go-to route for tendon, ligament, and soft tissue injuries.
- Oral/capsule form: 250–500 mcg per dose, 1–2x daily. Studied primarily for gastrointestinal applications. Direct contact with the GI lining is the proposed mechanism for gut healing.
- Intramuscular injection: 250–500 mcg per dose, typically 1–2x daily. Used less frequently, but some practitioners prefer it for deeper tissue injuries.
Subcutaneous injection provides higher local bioavailability compared to oral dosing. A Phase 1 study noted that no quantifiable BPC-157 was detected in plasma after oral administration, raising questions about systemic bioavailability through the oral route. But, this doesn't mean oral BPC-157 is ineffective for the gut, it may work precisely because it stays local to the GI tract.
Reconstitution is straightforward. A typical 5 mg vial mixed with 2 mL of bacteriostatic water yields 25 mcg per unit on a standard insulin syringe. A 250 mcg dose equals 10 units (tick marks). Store reconstituted vials at 2–8°C and use within 4 weeks.
Injectable BPC-157 vs. Oral BPC-157: Choosing the Right Form for Your Goal
The decision between injectable and oral BPC-157 comes down to one question: where is the problem?
For a torn rotator cuff, strained Achilles tendon, or nagging elbow tendinopathy, subcutaneous injection near the injury site is the clear choice. The peptide concentrates locally, upregulates VEGF at the tissue level, and promotes collagen synthesis where it's needed most.
For gut lining repair, whether it's NSAID-induced gastric damage, IBD symptoms, or chronic intestinal permeability, oral BPC-157 in capsule form makes more physiological sense. The peptide contacts the intestinal epithelium directly, which is where its protective effects on mucosal tissue have been most extensively demonstrated in preclinical models.
Some practitioners use both routes simultaneously for patients dealing with gut issues alongside a musculoskeletal injury. This is not uncommon, though no controlled combination studies exist to validate the approach.
Platforms like Peptide Injections AI can match patients with board-certified physicians who specialize in peptide therapy protocols, which helps remove the guesswork from selecting the right form and dosage for individual goals.
Recommended BPC-157 Dosing by Healing Goal
Different injuries and conditions call for different BPC-157 dosage strategies. Here's how experienced practitioners typically structure protocols based on the primary healing goal:
Tendon and Ligament Repair
- Dose: 250–500 mcg per injection
- Frequency: Twice daily (morning and evening, ~12 hours apart)
- Route: Subcutaneous, injected as close to the injury site as practical
- Cycle: 4–6 weeks, then reassess
This is the most well-studied application in animal models. Practitioners commonly see patients report noticeable pain reduction within 7–14 days and improved range of motion by week 3. A 500 mcg twice-daily protocol is standard for moderate-to-severe tendon injuries like Achilles tendinopathy or rotator cuff strains.
Gut Healing and GI Restoration
- Dose: 250–500 mcg per dose
- Frequency: 1–2x daily
- Route: Oral (capsule) preferred: subcutaneous also used
- Cycle: 4–6 weeks minimum, extendable for chronic conditions
For gut applications, oral administration on an empty stomach may improve direct contact with the intestinal lining. Some clinicians recommend pairing oral BPC-157 with KPV (an anti-inflammatory tripeptide) for patients with IBD-related inflammation, as KPV targets the NF-kB pathway through a different mechanism.
Post-Surgical Recovery
- Dose: 500 mcg, twice daily
- Frequency: Start within days of surgery (with physician guidance)
- Route: Subcutaneous near surgical site
- Cycle: 4–6 weeks
Post-surgical protocols are among the most popular use cases. The combination of BPC-157 with GHK-Cu (a copper-binding peptide that stimulates collagen synthesis) is frequently used for post-procedure healing, particularly after orthopedic surgeries.
The "Wolverine Stack" for Comprehensive Healing
For patients with multiple injury sites or systemic tissue damage, practitioners often combine BPC-157 with TB-500 (Thymosin Beta-4 fragment). BPC-157 handles local repair through VEGF and NO pathways, while TB-500 promotes systemic healing through actin dynamics and angiogenesis. A typical stack:
- BPC-157: 250–500 mcg subcutaneous, 2x daily
- TB-500: 750 mcg subcutaneous, 2x weekly (loading), then 1x weekly (maintenance)
No controlled combination studies exist for this stack, but it remains the most widely used peptide combination in sports medicine and recovery protocols.
Cycle Length, Timing, and What to Expect During Your Protocol
A standard BPC-157 cycle runs 4–6 weeks, followed by reassessment. Some practitioners extend to 8 weeks for severe or chronic conditions, while minor injuries may resolve in as little as 2–3 weeks.
The peptide's estimated half-life is approximately 4 hours, which is why twice-daily dosing is the standard recommendation. Splitting doses 12 hours apart maintains more consistent peptide levels throughout the day.
Timing recommendations:
- Injectable: Morning and evening, roughly 12 hours apart. No strict food timing required for subcutaneous administration.
- Oral: On an empty stomach, at least 30 minutes before meals. This maximizes direct contact with the GI lining.
What to expect, week by week:
- Week 1: Most people feel nothing dramatic. Some report mild warmth or tingling near the injection site. Gut protocol users occasionally notice reduced bloating.
- Weeks 2–3: This is where changes typically become noticeable. Tendon pain often decreases measurably. Gut symptoms like cramping or discomfort begin to improve.
- Weeks 4–6: Peak healing window. Range of motion improvements, reduced inflammation markers, and functional gains are commonly reported by this stage.
After completing a cycle, the standard approach is to reassess and either continue or take a break before repeating. There's no established mandatory off-cycle period for BPC-157, but many practitioners recommend 2–4 weeks off between cycles to maintain receptor sensitivity.
Bloodwork to consider:
- CBC with differential, baseline
- CMP (liver and kidney panels), baseline and at 4 weeks
- Fecal calprotectin, baseline and 4–6 weeks (for IBD-related gut protocols)
BPC-157 is generally well-tolerated. The most commonly reported side effects include mild injection site irritation, occasional nausea, and rare headaches. But, individuals with active cancer should avoid BPC-157 entirely due to its angiogenic potential, the same blood vessel formation that aids healing could theoretically promote tumor growth.
Common Dosing Mistakes That Can Stall Your Recovery
Even with a solid BPC-157 dosage plan, several common errors can significantly reduce results. Here are the ones practitioners see most often:
1. Inconsistent dosing schedules
BPC-157's short half-life (~4 hours) means skipping doses or dosing at irregular intervals leads to inconsistent peptide levels. Twice daily means twice daily, not "whenever I remember." Setting phone alarms for morning and evening doses is a simple fix that makes a real difference.
2. Choosing the wrong route for the condition
This one is surprisingly common. Someone with a patellar tendon injury taking oral BPC-157 capsules is not getting the peptide where it needs to go. Conversely, injecting subcutaneously in the abdomen for a gut-healing protocol misses the point of direct GI contact that oral administration provides.
Match the route to the target tissue. Tendon or ligament injury? Inject near the site. Gut issue? Go oral.
3. Dosing too high without reason
More is not better with BPC-157. The well-studied range is 250–500 mcg per injection. Pushing above 500 mcg per dose hasn't shown proportionally better outcomes in preclinical data, and it burns through supply faster. Start at 250 mcg twice daily and increase to 500 mcg only if response is insufficient after 2 weeks.
4. Neglecting sterile technique
Reconstituting peptides requires basic sterile handling: clean the vial stopper with alcohol swabs, use fresh needles for each injection, and never touch the needle tip. Contaminated vials can cause infection and degrade the peptide itself.
5. Skipping baseline bloodwork
Without a CBC and CMP at baseline, there's no way to track whether the protocol is affecting liver or kidney function. This is especially important for longer cycles or when stacking BPC-157 with other peptides like TB-500.
6. Not working with a qualified provider
BPC-157 is a Category 1 compoundable peptide, meaning it should be prescribed and overseen by a licensed physician. Self-prescribing based on internet forums introduces unnecessary risk. Services like Peptide Injections AI connect patients with specialized peptide therapy providers in about 2 minutes, offering personalized protocol recommendations from board-certified physicians who understand proper dosing, stacking, and monitoring.
Conclusion
Getting the BPC-157 dosage right isn't complicated, but it does require attention to detail. The 250–500 mcg twice-daily range remains the standard for both tendon repair and gut restoration, with the critical variable being route of administration matched to the healing goal.
Choose subcutaneous injection near the injury for musculoskeletal issues. Choose oral for gut healing. Run 4–6 week cycles, get baseline bloodwork, and work with a qualified provider who can adjust the protocol based on individual response.
The preclinical evidence behind BPC-157 is extensive and promising. But it is still preclinical. That's exactly why proper dosing, monitoring, and medical oversight matter, they're the difference between a well-run healing protocol and an expensive guessing game.
Frequently Asked Questions About BPC-157 Dosage
What is the standard BPC-157 dosage for tendon and ligament injuries?
The standard BPC-157 dosage for tendon and ligament repair is 250–500 mcg per injection, administered twice daily (morning and evening, approximately 12 hours apart) via subcutaneous injection near the injury site. A 4–6 week cycle is typical, with most practitioners starting at 250 mcg and increasing to 500 mcg if response is insufficient after 2 weeks.
How does the administration route affect BPC-157 effectiveness for different healing goals?
Subcutaneous injection near the injury site is ideal for tendon, ligament, and musculoskeletal damage because it concentrates the peptide locally and upregulates VEGF at the tissue level. Oral administration is better for gut healing because direct contact with the intestinal epithelium is the proposed mechanism. The route must match the target tissue for optimal results.
What is the BPC-157 half-life and why does dosing frequency matter?
BPC-157 has an estimated half-life of approximately 4 hours, which is why twice-daily dosing is the standard recommendation. Splitting doses 12 hours apart maintains consistent peptide levels throughout the day. Skipping doses or dosing irregularly leads to inconsistent peptide concentrations and significantly reduces healing outcomes.
Can genetic factors influence how well BPC-157 works for me?
Yes. Individuals with VEGFA (rs2010963) high-expression variants may respond more strongly to BPC-157, while carriers of the NOS3 G894T variant may experience slower healing responses due to impaired nitric oxide production. Genetic testing through specialized services can identify these differences before starting a protocol to optimize dosing and expectations.
What is the 'Wolverine Stack' and is it safe to combine BPC-157 with other peptides?
The 'Wolverine Stack' combines BPC-157 (250–500 mcg subcutaneous, 2x daily) with TB-500 (750 mcg subcutaneous, 2x weekly loading, then 1x weekly maintenance). BPC-157 handles local repair through VEGF and nitric oxide pathways, while TB-500 promotes systemic healing. However, no controlled combination studies exist for this stack, so it should only be used under physician guidance.
What baseline bloodwork should I get before starting a BPC-157 protocol?
Before starting BPC-157, obtain baseline CBC (complete blood count) with differential and CMP (comprehensive metabolic panel including liver and kidney function). Repeat the CMP at 4 weeks during your protocol. For gut-healing applications, also get baseline fecal calprotectin at baseline and 4–6 weeks to track inflammation markers and safety.